Immunopathology and Hypersensitivity
Immunopathology is the study of how the immune system causes, rather than prevents, tissue injury. Hypersensitivity reactions are exaggerated or misdirected immune responses that damage host tissues, and they are conventionally grouped into four mechanistic categories (Types I-IV) following the Gell and Coombs classification. This area also encompasses autoimmunity, in which immune effectors are directed against the body's own constituents.
Definition
Immunopathology and hypersensitivity refers to tissue injury and disease produced by immune responses that are excessive, prolonged, or directed against self or harmless antigens, classically organised into the four Gell and Coombs hypersensitivity types and the related phenomenon of autoimmunity.
Scope
This area orients the reader to the mechanisms by which immune responses produce disease: immediate IgE-mediated reactions, antibody-mediated cytotoxicity, immune-complex deposition, delayed cell-mediated injury, and the breakdown of self-tolerance that underlies autoimmune disease. It frames these as pathophysiologic categories within general pathology and links to the individual topic entries that develop each in detail. It is a reference overview, not clinical guidance.
Sub-topics
Core questions
- Which immune effector mechanism (IgE, antibody, immune complex, or T cell) mediates the tissue injury?
- Is the target antigen foreign (allergen, microbe, drug) or self?
- What distinguishes a protective immune response from a pathological one?
- How does loss of immunological tolerance lead to autoimmune disease?
Key concepts
- Hypersensitivity Types I-IV
- Immune-mediated tissue injury
- Allergen and self-antigen
- Immunological tolerance and its breakdown
- Autoimmunity
- Effector mechanisms: IgE, antibody, immune complex, T cell
Key theories
- Gell and Coombs classification of hypersensitivity
- Coombs and Gell proposed four categories of immune-mediated tissue injury distinguished by effector mechanism: Type I (IgE/mast cell), Type II (antibody-mediated cytotoxicity), Type III (immune complex), and Type IV (T cell-mediated, delayed). The scheme remains the standard organising framework for hypersensitivity.
Mechanisms
Immune effector mechanisms that normally clear pathogens can injure host tissue when they are excessive or misdirected. In Type I reactions, antigen cross-links IgE bound to mast cells and basophils, triggering rapid mediator release. In Type II, antibody binds cell-surface or matrix antigens and recruits complement and effector cells to destroy them. In Type III, antigen-antibody complexes deposit in vessels and tissues and incite complement-driven inflammation. In Type IV, sensitised T cells drive delayed inflammation through cytokine release and direct cytotoxicity. Autoimmunity arises when central and peripheral tolerance fail and these same effector pathways are directed against self-antigens.
Clinical relevance
Understanding which hypersensitivity mechanism is operating helps explain the tempo, histology, and serology of immune-mediated disease and underpins how disorders such as allergy, transfusion reactions, immune-complex vasculitis, contact dermatitis, and autoimmune disease are categorised. This entry describes mechanisms for educational orientation and is not a basis for individual diagnosis or treatment.
Epidemiology
Immune-mediated diseases are collectively common: allergic conditions affect a large fraction of the population, and autoimmune diseases together affect several percent of people, with many showing a female predominance. Precise burden varies by specific disease and is addressed in the individual topic entries.
Evidence & guidelines
The mechanistic framework summarised here derives from immunology textbooks and review syntheses rather than from trials; disease-specific evidence and guidelines are covered in the relevant topic and clinical-entity entries.
History
The recognition that immune responses can harm the host dates to early-twentieth-century observations of anaphylaxis and serum sickness. Coombs and Gell consolidated these phenomena in 1963 into a four-type classification of hypersensitivity that has structured immunopathology teaching ever since, later extended by molecular understanding of tolerance and autoimmunity.
Debates
- How adequate is the four-type Gell and Coombs scheme today?
- The classification predates modern knowledge of T-helper subsets, innate immunity, and cytokine biology; many diseases involve overlapping mechanisms, and some authors propose subdividing Type IV or adding categories, while the original scheme remains the dominant teaching framework.
Key figures
- Robin Coombs
- Philip Gell
- Abul Abbas
Related topics
Seminal works
- coombs-gell-1963
- davidson-diamond-2001
Frequently asked questions
- What are the four types of hypersensitivity?
- In the Gell and Coombs scheme, Type I is immediate IgE-mediated, Type II is antibody-mediated cytotoxicity, Type III is immune-complex mediated, and Type IV is delayed, T cell-mediated. Autoimmune diseases often involve Type II, III, or IV mechanisms directed against self.
- How does hypersensitivity differ from autoimmunity?
- Hypersensitivity describes the effector mechanism of immune-mediated tissue injury and can be triggered by foreign or self-antigens; autoimmunity specifically refers to immune responses directed against the body's own antigens, which then cause injury through one or more of those same mechanisms.